Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization.
BACKGROUND
Enumeration of CD34+ cells in peripheral blood (PB) before apheresis predicts the number of CD34+ cells collected, although flow cytometric techniques used are complex and expensive. In an attempt to determine the optimal timing for peripheral blood progenitor cell (PBPC) collection, the usefulness of circulating immature cell (CIC) counts in PB was evaluated.


METHODS
CIC counts in PB and CD34+ cell counts in the apheresis product from 249 collections were assessed, and the relationship between these two parameters was evaluated by with the Pearson rank correlation analysis, the Fisher exact test, and the U-test.


RESULTS
CIC counts were correlated significantly with the number of CD34+ cells per kg of patient's body weight in the apheresis product (Pearson rank correlation analysis: r = 0.635, p < 0.0001). When a level of 1 x 10(9) CICs per L was selected as a cutoff value, the sensitivity and specificity for collecting more than 1 x 10(6) CD34+ cells per kg of body weight were 75.7 and 85.5 percent, respectively.


CONCLUSIONS
The present study strongly suggests that the number of CICs in PB may estimate the number of CD34+ cells collected. The data indicate that CIC counts above 1 x 10(9) per L can be used as a good predictor for PBPC collections containing more than 1 x 10(6) CD34+ cells per kg of body weight in a single apheresis procedure.
Kozuka
Teruhiko
T
Second Department of Internal Medicine, Okayama University Medical School, Okayama, Japan. kozuka@md.okayama-u.ac.jp
Ikeda
Kazuma
K
Teshima
Takanori
T
Kojima
Kensuke
K
Matsuo
Keitaro
K
Bessho
Akihiro
A
Sunami
Kazutaka
K
Hiramatsu
Yasushi
Y
Maeda
Yoshinobu
Y
Noguchi
Toshio
T
Yamamoto
Kazuhiko
K
Fujii
Nobuharu
N
Imai
Toshi
T
Takenaka
Katsuto
K
Shinagawa
Katsuji
K
Ishimaru
Fumihiko
F
Niiya
Kenji
K
Koide
Norio
N
Tanimoto
Mitsune
M
Harada
Mine
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001772:Blood Cell Count; D016922:Cellular Senescence; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D005047:Etoposide / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000494:pharmacology; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D011237:Predictive Value of Tests; D012372:ROC Curve; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003907:Dexamethasone; D007069:Ifosfamide